OS for Black patients was 57.8 months in those with a favorable ELN cytogenic RS, 14.2 months for those with intermediate RS ...

The Ivanhoe Atlantic/HPX concession faces significant hurdles due to the lack of formal Guinean approval and unresolved issues regarding third-party rail access, particularly the involvement of AML.By ...

The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...

The mortality-to-incidence ratio initially increased in the early 2000s, declined sharply between 2008 and 2011, and remained stable thereafter.

Black race is an independent prognostic factor for shorter survival in acute myeloid leukemia independent of cytogenetic ...

At a data cut-off of 37.3 months, EFS improved to 3.4 months for crenolanib, compared with 0.0 months for placebo.

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger ...

PRESS RELEASEAB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A ...

In updated 2025 American Society of Hematology guidelines, recommendations are presented for the management of newly ...

The RAINIER study continues to enroll patients across additional dose levels. Mipletamig's design leverages Aptevo's ADAPTIR (TM) platform to deliver targeted T-cell engagement with the goal of ...